The Prostate Cancer Prevention Trial (PCPT) was initiated in 1994 with the aim of determining whether the 5a reductase inhibitor finasteride reduces the risk of prostate cancer. A report recently published concludes that finasteride prevents or delays the appearance of prostate cancer, but this benefit together with a reduced risk of urinary problems has to be balanced against potential sexual side effects and the increased risk of high-grade prostate cancer (Thompson et al, N Engl J Med 2003; 349: 211-220). A total of 18 882 men aged 55 y or over randomised to placebo or treatment with finasteride, 5 mg/day, over a 7-y study; the inclusion criteria included a normal digital rectal examination (DRE), no clinically significant coexisting conditions and an American Urological Association symptom score of o20. All men underwent annual DRE and prostate-specific antigen (PSA) measurement after their initial assessment. PSA levels in men treated with finasteride were adjusted upwards by a factor of 2.3 to allow for the reduction in PSA levels that have been noted with the drug. Prostate biopsy was performed on men with an abnormal DRE or if t he PSA level was 44 ng/ml. All men who had not undergone a prostate biopsy were offered one at the end of the study.
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Data were reported on 9060 men who have completed 7 y of the study. Prostate cancer was detected in 803 of the 4368 (18.4%) men treated with finasteride and 1147 of the 4692 (24.4%) men in the placebo group (Po0.001). Prostate cancer was detected in 435 (of 1639) and 571 (of 1934) men during the course of the study in finasteride-and placebo-treated men, respectively, and in 368 (of 3652) and 576 (of 3820) men, respectively, during the end of the study biopsy at the end of the study. This represents an overall relative risk reduction of 24.8% with finasteride (Po0.001). No significant difference was observed between the two groups in the number of men recommended for biopsy.
An initial PSA adjustment factor of 2.0 was used in men in the finasteride group, but this was changed to 2.3 during the fourth year of treatment in order to balance the number of biopsies performed in the two groups. If the factor of 2.0 had been used throughout the study, then 22 men in the finasteride group would not have undergone biopsy. With the change in the adjustment factor, 69 men underwent biopsy and 17 cases of prostate cancer were detected. There was a greater proportion of tumours with Gleason scores 7-10 in the finasteride group (37%) than in the placebo group (22.2%) (Po0.001). A total of 97.7% of cancers found in the finasteride group were T1 or T2 as well as 98.4% of those in the placebo group. The median prostate volume was 25.5 and 33.6 ml in men in finasteride and placebo groups, respectively.
With regard to side effects, reduced volume of ejaculate, erectile dysfunction, loss of libido and gynaecomastia were more common in the finasteride group (Po0.001). This contrasts with a greater incidence of urinary urgency, urinary frequency, prostatitis, urinary tract infection and urinary retention in the placebo group (Po0.001). Five men in each group died of prostate cancer. Although the risk reduction observed with finasteride is clinically significant, further analysis of the biologic effects of therapy on grade is required before widespread recommendations for prophylatic use can be made. While the increased risk of Gleason scores 47 may be due to the well known antiandrogen effect on glandular morphology, additional biomarker analyses, such as p27, Ki-67, are required.
Prostate cancer screening
Punglia et al (N Engl J Med 2003; 349: 393-395) report on the sensitivity and specificity of the PSA screening test for prostate cancer after correction for verification bias, that is, the lack of confirmation of disease status in all patients. A total of 705 men from a cohort underwent prostate biopsy on the basis of PSA screening. A mathematical model to estimate adjusted receiver-operating-characteristic (ROC) curves was used under the assumption that the chance of undergoing a biopsy depends only on the PSA-test result and other observed clinical variables. It was observed that adjusting for verification bias significantly increased the area under the ROC curve (ie, the overall diagnostic performance) of the PSA test, as compared with an unadjusted analysis. If the threshold PSA value for undergoing biopsy was set at 4.1 ng/ml, 82% of cancers in men aged o60 y and 65% of cancers in men aged 460 y would be missed. The authors of the report suggest that the clinical value of the PSA test may be improved by using a lower threshold level of PSA for recommending prostate biopsy, particularly in younger men.
However, this recommendation for lowering of the PSA threshold for biopsy must be balanced by the increased risk for diagnosis of more and potentially insignificant cancers as more biopsies are performed, as illustrated in the PCPT by Thompson et al described above.
hK2 and PSA screening Glandular kallikrein has been shown to enhance the specificity of PSA testing (Becker et al. J Urol 2003; 170: 1169 -1174 . A randomly selected group of 9811 men aged 50-66 y in Sweden were screened for PSA during 1995-96. Total PSA level of 43 ng/ml was measured in 660 men and prostate cancer detected in 145 of the 611 men who underwent prostate biopsy. PSA screening was conducted 2 y later on the men who had an original negative biopsy. In addition, hK2, percent free PSA (fPSA) and hK2 Â tPSA:fPSA were measured. The results indicated that hK2 enhanced the specificity in this group of men compared with tPSA. Levels of hK2 and hK2 x tPSA:fPSA increased significantly more at 2 y in men with cancer than in those with benign biopsies.
New protein markers for prostate cancer
A study shows that novel serum protein can distinguish men with prostate cancer (Lehrer et al, Br J Urol Int 2003; 92: 223-225) . Serum protein analysis has been conducted on 11 men with localised prostate cancer, 12 men with BPH and 12 disease-free controls. The protein-chip array surface-enhanced laser desorption/ionisation (SELDI) technique was used in the analysis. In men with prostate cancer and BPH, three protein peaks were identified with molecular masses of 15.2, 15.9 and 17.5 kDA. There was a significant association with these protein and prostate cancer and BPH compared with controls. The 17.5 kDA protein was more abundant in five men with T1 disease than in the eight men with T2 disease (P ¼ 0.016), while the 15.9 kDA protein might be useful for differentiating prostate cancer from BPH.
DD3
PCA3 urine diagnostic marker for prostate cancer Hessels et al (Eur Urol 2003; 44: 8-16 ) report on the clinical utility using a fluorescence-based reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. The study was based on a cohort of 108 men admitted for prostate biopsy based on a PSA 43 ng/ml. DD3 PCA3 transcripts were determined in urine sediments obtained after prostatic massage and in nonmalignant and malignant prostate specimens. The results showed that prostate tumours had a 66-fold upregulation of DD3 PCA3 compared with benign tissue. In addition, specimens with less than 10% of cancer cells could be accurately distinguished from noncancer tissues. Prostate cancer was detected in 24 men on biopsy. Of these, 16 had a positive urine test for DD3 PCA3 indicating a sensitivity of 67%; a negative predictive value of 90% was also calculated. The authors conclude that the RT-PCR assay for DD3
PCA3 is a potential new tool for molecular urine analysis and may assist in reducing unnecessary biopsies.
Age and PSA as predictors of organconfined disease
Predictors of organ-confined prostate cancer have been studied in a database of 3198 patients from five institutions who underwent radical prostatectomy between 1995 and 2001; pretreatment PSA was o10 ng/ml (Aleman et al, Urology 2003; 62: 70-74) . A linear relationship between age and risk of non-organ-confined disease was identified in the 29% of patients who had non-organconfined disease. Other tested variables were independent multivariate predictors of non-organ-confined disease: age (P ¼ 0.004); year (Po0.0001); PSA (Po0.0001); Gleason sum (Po0.0001) and clinical stage (Po0.0001). For PSA levels between 0.1 and 4.0 ng/ml, the likelihood of non-organ confined disease remained constant, but increased substantially for PSA levels 44.0 ng/ml. It was concluded that younger men with a lower PSA level are more likely to have organ-confined, curable disease at diagnosis and this should be considered when counselling on treatment decisions.
Nomogram for positive repeat biopsy
Researchers at the Sloan-Kettering Cancer Center, New York, USA have developed a nomogram for predicting a positive biopsy after a previous negative biopsy ( LopezCorona et al, J Urol 2003; 170: 1184 -1188 . Data from 343 patients were studied; the mean number of biopsy sessions was 2.9 per patient with a mean of 9.15 cores per biopsy. Overall, 20% of patients had prostate cancer at the second biopsy session. Repeat biopsy findings were associated with the following factors: cumulative number of negative cores; PSA slope; history of highgrade prostatic intraepithelial neoplasia; and history of atypical small acinar proliferation (Po0.05 all factors). The nomogram constructed had a concordance of 0.70 and may assist in clinical decision making on repeat biopsies.
Seven-year follow-up after benign prostate biopsy Boddy et al (Eur Urol 2003; 44: 17-20) report on the 7-year follow-up of 164 men aged o80 y with an elevated PSA level, who had a benign biopsy recorded between 1994 and 1995. In all, 18 (11%) patients were subsequently diagnosed with prostate cancer and two died from the disease. Most of the cancers diagnosed at follow-up were clinically significant and a small proportion progressed rapidly to metastases. The authors of the report recommend an initial intense period of PSA monitoring in patients with elevated PSA but a benign biopsy to establish that the PSA, level is not rising and to avoid missing clinically aggressive disease.
Sexual factors and prostate cancer
Giles et al (Br J Urol Int 2003; 92: 211-216 ) report on the number of sexual partners and the frequency of total ejaculations during the third to fifth decades of life in a case-control study of men with prostate cancer aged o70 y at diagnosis and age-matched control subjects. Overall, no association of prostate cancer with the number of sexual partners or with the maximum number of ejaculations in a 24 h period was observed. There was What's hot in the prostate M Gleave and CP Evans a negative trend (Po0.01), however, for the association between the risk and number of ejaculations in the third decade, independent of those in the fourth or fifth. Men who averaged five or more ejaculations weekly during their 20 s had an odds ratio (95% confidence interval) of 0.66 (0.49-0.87) compared with those who ejaculated less often. These findings suggest that ejaculatory frequency, especially in early adult life, is negatively associated with the risk of prostate cancer.
Laparoscopic radical prostatectomy
A number of reports have been published recently on laparoscopic radical prostatectomy including the functional outcome compared with retropubic radical prostatectomy. One study involved 70 patients treated with retropubic and 230 with laparoscopic radical prostatectomy during 1998-2002 (Anastasiadis et al, Urology 2003; 62: 292-297). A self-administered questionnaire sought information on urinary continence and erectile function up to 12 months after surgery. Prior to surgery, 98.7% of patients were continent and 96.6% were potent. The duration of bladder catheterisation was shorter in the laparoscopic group of patients: 7.8 and 5.8 days for the retropubic and laparoscopic approaches, respectively. Continence and potency rates at baseline and at 1 y after surgery are shown below.
Potency rates were higher if one or two neurovascular bundles were preserved: 27 and 46% for the retropubic approach and 44 and 53% for the laparoscopic approach. The recovery of nocturnal continence appeared to occur earlier in patients treated laparoscopically and this aspect warrants further study. An analysis of factors affecting operating time for laparoscopic radical prostatectomy has been reported by El-Feel and co-workers (Urology 2003; 62: 314-318). A comparison was made of operating times (OT) achieved by two experience surgeons, who had performed more than 100 procedures previously, and two junior surgeons, who had performed less than 30 procedures. Prior androgen deprivation or abdominal surgery did not significantly affect the OT for the 62 patients operated on by the senior surgeons and the 38 operated on by the junior surgeons; grade 1 obesity increased the OT by an average of 38 min. The mean OT for experienced and junior surgeons was 214 and 347 min, respectively (Po0.001). A multiple regression model with stepwise selection indicated that prostate weight, sural nerve grafting, pelvic lymph node dissection, use of surgical robot and surgeon experience significantly affected the OT.
A report has been made on the management of rectal injuries during laparoscopic radical prostatectomy by Katz et al (Urology 2003; 62: 310-313). The study involved 300 patients who underwent surgery between May 1998 and June 2002. All patients underwent bowel preparation and received perioperative antibiotics. DRE was performed in the case of suspected rectal injury and on confirmation, the hole was closed in two layers of absorbable sutures. A fat flap was developed from the omentum (in the transperitoneal approach) or the perirectal fat (in the extraperitoneal approach) and placed on the suture line, and anal dilation was conducted. Broad-spectrum antibiotics and a low-residue diet were prescribed after surgery. Rectal injury occurred in six (2%) patients; five cases were in the transperitoneal approach and were closed using omental fat and one was in the extraperitoneal approach with a perirectal fat flap. The first patient presented with a rectourethral fistula and was treated with catheterisation for 1 month and a diverting colostomy. The others were detected intraoperatively and were treated laparoscopically. Patients resumed oral intake within 2-7 days and were discharged from the hospital between 6 and 18 days postoperatively. No wound infection was noted. The authors conclude that rectal injuries during laparoscopic radical prostatectomy can be identified and managed intraoperatively without requiring conversion.
Chromogranin A levels and hormonal therapy
Sciarra et al (Prostate 2003; 55: 168-179) have reported that intermittent maximum androgen blockade (MAB) does not result in the increased level of chromogranin A (CgA) observed with continuous MAB. Continuous androgen suppression has been thought to cause hyperactivation of neuroendocrine cells and an increase in CgA. Two groups of patients who had previously responded to 24 months of intermittent androgen suppression (IAD) were enrolled in the study: pT3pN0M0 with biochemical progression after radical retropubic prostatectomy (Type 1) and metastatic prostate cancer patients treated with MAB (Type 2). All patients were randomly assigned to IAD or continuous MAB. Of the 40 patients reported on in each group, a significant trend towards increased CgA levels from baseline to 24 months of treatment was observed in the continuous MAB group. In contrast, there was no increase in CgA in patients treated with IAD and levels were significantly lower than in the continuous group (Po0.005). These findings would suggest that IAD may delay the progression of prostate cancer to androgenindependence because CgA is a marker for neuroendocrine differentiation of prostate cancer, well known to be associated with progression to the androgen independent state.
PROnet: new patient survey
PROnet is a new global network of organisations working with men living with prostate cancer, their partners, families and friends. The network, established in 2000, was formed in order to share information and best practice about prostate cancer awareness, early of the risk of prostate cancer, rating the disease as the third most serious condition after lung cancer and heart disease. There was a good understanding of the symptoms of the disease, with threequarters citing urinary irregularities as a potential disease marker. Despite regarding prostate cancer as a serious condition, the majority of men (61%) are unable to name a single treatment for the disease. When prompted, men were more likely to be familiar with treatments such as surgical prostate removal (77%) than medical therapies or radiotherapy. Portuguese men had the lowest awareness of both the detection and treatment of prostate cancer with 7% unable to name a single symptom and, even when prompted, 22% were unable to recognise a single intervention. In all, 50% of men questioned viewed increased survival as a priority for prostate cancer treatment. Although the majority of men (67%) would feel comfortable discussing their genitourinary health with a doctor, regional variations were observed. Men in the UK and Italy felt most comfortable talking to their doctor about such issues, while those from Germany, Austria and The Netherlands were least comfortable.
PROnet have also launched a blue version of the pink ribbon commonly associated with breast cancer. Adhering to the adage 'pink for girls and blue for boys', it is hoped that the ribbon will become synonymous with the most common cancer exclusive to men and create greater awareness and encourage open discussion about the disease, leading to earlier detection, treatment and improved survival rates.
Five-year follow-up on TUNA patients
Five-year follow-up has been reported for 188 consecutive patients treated with symptomatic BPH treated with transurethral needle ablation (TUNA) of the prostate at three different centres in Europe (Zlotta et al, Eur Urol 2003; 44: 89-93) . The results show that the mean peak urinary flow rates increased from 8.6 to 12.1 ml/s and International Prostate Symptom Score (IPSS) and postvoid residual urine decreased from 20.9 and 179 ml to 8.7 and 122 ml, respectively. An increase of at least 50% in the peak flow rate and IPSS was recorded in 24 and 78% of patients, respectively. No significant changes in PSA or prostate volume were achieved. Overall, 41 (23.3%) patients required additional treatment (medical, TUNA or surgery). These results would suggest that TUNA is a durable therapy and is associated with a low failure rate.
HoLEP: morbidity rates
A retrospective analysis of 206 holmium laser procedures carried out between April 1999 and October 2001 has been conducted in terms of complications associated with the Holmium laser enucleation of the prostate (HoLEP) procedure (Kuo et al, Urology 2003; 62: 59-63) . The mean patient age was 70.5 y and the mean specimen weight was 68.2 g (range 3-376 g); 20 patients were diagnosed with adenocarcinoma. The other findings were: the mean hospital stay of 1.1 days; 86.9% of patients discharged without a catheter and two (1%) patients required a postoperative blood transfusion. No major complications or deaths were reported. Intraoperative complications comprised one bladder neck false passage; four incomplete morcellations; three capsular perforations and four minor bladder mucosal morcellation injuries. Long-term complication data were available from 173 patients and included: five urethral strictures; five clot retention episodes; eight bladder neck contractures and recatheterisation in 16 patients.
Alfuzosin for the treatment of prostatitis/pelvic pain A placebo-controlled study has been reported on the a 1 blocker alfuzosin in 70 patients with chronic prostatitis/ chronic pelvic pain syndrome (CP/CPPS) (Mehik et al, Urology 2003; 62: 425-429) . Data on 66 patients show that after 6 months of therapy with alfuzosin, there was a significant decrease in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) compared with placebo: À9.9 vs -3.8 points (P ¼ 0.01). A statistically significant improvement occurred in the pain score in the alfuzosin group at 6 months compared with the placebo group (P ¼ 0.01), but not in the voiding or quality-of-life score among the three groups. At 6 months after the alfuzosin/placebo treatment was discontinued, the symptom scores in all domains of the NIH-CPSI showed deterioration compared with original baseline score in the alfuzosin and placebo groups; -3.5 and -0.1 points below baseline, respectively. One patient in the alfuzosin group experienced gastrointestinal symptoms and four reported a decrease in ejaculate volume. The authors conclude that alfuzosin therapy for CP/CPPS is safe and well tolerated and provides a small, but statistically significant, improvement in the NIH-CPSI, particularly in the pain domain, compared with placebo. This beneficial effect is lost when treatment is discontinued.
